- Home
- FONR vs NRXP Comparison
FONR vs NRXP Comparison
Compare FONR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FONR | NRXP |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | 535 | 29 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 99.2M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | FONR | NRXP |
|---|---|---|
| Price | $18.89 | $3.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 54.3K | ★ 1.0M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $104,351,318.00 | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | $16.29 | ★ N/A |
| Revenue Growth | ★ 1.43 | N/A |
| 52 Week Low | $13.62 | $1.65 |
| 52 Week High | $18.95 | $3.84 |
Technical Indicators
Market Signals| Indicator | FONR | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 61.28 |
| Support Level | $18.31 | $2.78 |
| Resistance Level | $18.95 | $3.33 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 65.83 | 62.50 |
Price Performance
Historical ComparisonAbout FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.